author-photo

Aruna Mehra

Bayer HealthCare Pharmaceuticals

5

Papers

12

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (9)
CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

2017 Blood
Show All
- Source
- Cite
- Save
Citations (3)